Positiv
●
Reuters
●
vor 5 Monaten
Roche said on Friday that patients lost 22.7% of their body weight in a mid-stage trial of its dual-acting experimental obesity drug, with more than a quarter of those who received the highest dose achieving at least 30% weight loss.